Golik Holdings Limited Overview
Golik is a family-controlled, Hong Kong-headquartered industrial holding company with two cash-generative legacy franchises and one nascent healthcare bet. Its largest business by revenue is the supply of building construction materials in Hong Kong — ready-mixed concrete, precast products and the distribution and off-site cut-and-bend processing of reinforcing steel — where it has operated for more than four decades. Its higher-margin franchise is steel wire and steel wire rope manufacturing in Tianjin, Heshan and Jiangmen in Mainland China, historically anchored by elevator ropes (the Group describes its Tianjin unit as China's first elevator-rope manufacturer) and increasingly by high-performance lifting ropes sold to global equipment OEMs including Caterpillar. In November 2024 it opened Assure Medical Imaging (AMI), a PET-CT/MRI/CT centre in Tsim Sha Tsui. The Group trades at roughly 0.45x book and ~4.4x earnings with a net cash balance sheet, reflecting its small size, illiquidity, concentration in a contracting Hong Kong construction market, and controlling-family ownership.
Company's own description (paraphrased from AR25 Ann.)
In its FY2025 announcement Golik identifies three core businesses: metal products, building construction materials, and medical imaging services. The metal products business consists mainly of steel wire and steel wire rope products manufactured at three Mainland Chinese locations (Tianjin, Heshan and Jiangmen). The building construction materials business comprises ready-mixed concrete, precast concrete products, and the processing and distribution of construction steel products in Hong Kong. The medical imaging business provides CT, MRI and PET scanning in Hong Kong. Management describes its strategic emphasis as premium products and value-added services in both legacy businesses rather than competing purely on price. A small money-lending operation (Golik Capital Limited, licensed under Hong Kong's Money Lenders Ordinance) lends to business associates referred by Group companies and is reported as "other operation".
Independent characterisation
Golik is best understood as a regional industrial distributor-processor-manufacturer with the following economic structure:
- Building construction materials (66% of FY2025 external revenue). Fundamentally a volume- and logistics-driven business tied to Hong Kong construction activity. Revenue is recognised on delivery; contracts are typically multi-year supply agreements for specific projects (remaining performance obligations of HK$1,604.4 M at end-FY2025, AR25 Ann.). Gross margin is driven by the spread between contracted selling prices and steel/cement/aggregate input costs; the FY2025 provision for onerous contracts of HK$55.8 M within this segment demonstrates the downside of fixed-price long-dated supply contracts when costs or competitive pricing move adversely. Value-added processing (cut-and-bend rebar) and transportation have been built up as differentiators.
Metal products (33% of FY2025 external revenue): A genuine manufacturing franchise with technical credentials: national-level "single-field manufacturing champion" recognition (2022), participation in drafting ISO 4344:2022 for elevator wire ropes, Tianjin Key Laboratory status, and a High and New Technology Enterprise (HNTE) tax status in Tianjin. The mix is shifting from domestic elevator ropes (structurally challenged by China's property downturn) toward high-performance lifting ropes for construction machinery and export markets (US revenue HK$134.5 M in FY2025, +21.8% YoY).
Medical imaging (1% of FY2025 external revenue): A capital-intensive diversification into Hong Kong private diagnostics, operating a single flagship centre on a referral model centred on local specialist doctors. EBITDA-positive in FY2025 but loss-making after depreciation, and its fixed assets were impaired by HK$15.3 M in FY2025.
Revenue model mix
| Revenue type (FY2025, HKD Mn) | Amount | % of total | Source |
|---|---|---|---|
| Product sales — steel wire / wire rope (incl. residual steel coil processing line item) | 1,175.9 | 32.5% | AR25 Ann. note 3 |
| Product sales — concrete products | 685.9 | 19.0% | AR25 Ann. note 3 |
| Product sales — construction steel products & processing, other construction products (incl. processing & transport service income, as re-presented in FY2025) | 1,712.7 | 47.4% | AR25 Ann. note 3 |
| Service income — medical imaging | 41.4 | 1.1% | AR25 Ann. note 3 |
| Interest income — money lending | 0.3 | <0.1% | AR25 Ann. note 3 |
| Total | 3,616.1 | 100% | — |
There is no subscription or licensing revenue. All revenue is recognised at a point in time (FY2025 policy; in FY2024 medical services had been recognised over time). Credit terms are 30–180 days. No single customer exceeded 10% of revenue in any year reviewed.
Value-chain position and customers
| Business | Upstream inputs | Golik's role | Customers / end-markets |
|---|---|---|---|
| Steel wire rope | Wire rod (steel), zinc for galvanising | Drawing, galvanising, stranding, closing ropes; R&D | Elevator OEMs and maintenance companies (China, export); construction machinery OEMs (e.g. Caterpillar); cranes; historically oilfield ropes (per Simply Wall St company profile) |
| Construction steel | Rebar from mills/traders | Stockholding, distribution, off-site cut-and-bend processing, delivery | Hong Kong main contractors and subcontractors on public and private projects |
| Concrete | Cement, aggregates, admixtures | Batching, delivery of ready-mixed concrete; precast products | Hong Kong contractors; historically Macau projects |
| Medical imaging | Imaging equipment (PET-CT, MRI, CT, ultrasound, mammography, DEXA, X-ray), radiologists | Diagnostic imaging, reporting | Patients referred by specialist doctors; insurers (collaboration under development) |
Strategy
Stated strategy themes (paraphrased from FY2023–FY2025 announcements)
-
Prudent operation and quality over scale. In FY2023 management articulated a principle of "prudent operation", prioritising operational efficiency and value-added service over volume; in FY2024 it described a "seeking progress while maintaining stability" approach with lean operations.
-
Premium products and value-added services. FY2025 strategy centres on premium products and value-added services across both the Mainland wire rope business and the Hong Kong building materials business, explicitly avoiding pure price competition.
-
Mix shift to high-performance wire ropes and exports. Promotion of high-performance elevator ropes to maintenance and export markets (Southeast Asia) and expansion of high-performance lifting ropes; withdrawal from markets where elevator rope prices fell below cost (H1 2025).
-
Diversification into healthcare. Establishment of AMI as a new long-term operating business; FY2023 outlook flagged exploring "new and high-quality investment opportunities".
-
Balance-sheet conservatism. Deleveraging and internal funding of capex.
Initiative register (last 24 months and relevant prior)
| Initiative | Timing | Detail | Status | Source |
|---|---|---|---|---|
| Assure Medical Imaging (AMI) | Invested 2024; launched Nov 2024 | One-stop imaging centre (PET-CT, MRI, CT etc.) in TST; referral model built around local specialists | Revenue HK$41.4 M FY2025; EBITDA positive; PPE impaired HK$15.3 M | AR24 Ann.; AR25 Ann. |
| AMI operational optimisation & insurer partnerships | H2 2025 onward | Improve throughput; expand collaborations with insurance providers; explore new business development | Ongoing; counterparties not disclosed | IR25 Ann. |
| Market exit — sub-cost elevator rope markets | H1 2025 | Withdrawal from certain loss-making elevator rope markets | Executed | IR25 Ann. |
| Export push — Southeast Asia | FY2024 onward | High-performance steel wire products to Indonesia, Vietnam and wider SE Asia | Ongoing | AR24 Ann. |
| Product innovation investment | FY2025 onward | Further investment in wire rope innovation and market expansion to consolidate leadership in domestic high-performance segment | Ongoing; spend not disclosed | IR25 Ann. |
| New RMC production line | Q1 2023 | Capacity expansion for Hong Kong ready-mixed concrete | Completed | AR22 Ann. |
| Share option scheme renewal | 14 Jun 2024 | Incentive framework | Adopted; no grants evident | AR24 Ann. |
| ESG reporting expansion | FY2025 | ESG boundary extended to all Hong Kong operations; first Scope 3 disclosure; qualitative climate-risk assessment | Completed | FY2025 AR summary (sustainabilityreports.com) |
Medium-term targets / guidance
Golik provides no quantitative financial targets or guidance. FY2026 qualitative outlook (AR25 Ann.): operating environment expected to remain challenging and uncertain, with downward pressure from competition and uncertainty over exports of certain products to the US; management intends to keep implementing its premium-products strategy to maintain stable performance. Cost programmes with numeric targets: none disclosed.
Products & Services
Golik does not publish product price lists or SKU-level revenue. The catalogue below is compiled from results announcements, annual-report business profiles and third-party company profiles.
Metal products segment
| Product line | Description & capabilities | Target customer | Status / latest data point | Pricing model |
|---|---|---|---|---|
| Elevator wire ropes | Steel wire ropes for traction elevators; Tianjin unit described as China's first elevator rope maker; Group drafted ISO 4344:2022 | Elevator OEMs (new installations), maintenance/modernisation market, export | Volume flat in FY2025 but profit contribution declined; certain loss-making markets exited in H1 2025 (IR25 Ann.) | Contract/tender pricing; not disclosed |
| High-performance elevator wire ropes | Premium elevator ropes promoted to maintenance and export markets | Maintenance companies; Southeast Asia (Indonesia, Vietnam cited) | Management "ramped up promotion" in FY2024 (AR24 Ann.) | — |
| High-performance lifting wire ropes | Ropes for cranes and construction machinery, developed principally in Tianjin | Construction-machinery OEMs (Caterpillar named), crane makers, export | Volume and profit up moderately in FY2025; Caterpillar Supplier Excellence Recognition FY2024 and FY2025 | — |
| Galvanised steel wire | Galvanised wire production line (pictured in AR21/AR22 business profile) | Internal use and external wire customers | Ongoing | — |
| Crane and oilfield ropes | Listed in third-party profiles (Simply Wall St) | Crane operators, oil & gas | — | — |
| Pre-stressed (PC) steel strand | Historically produced by Tianjin Golik – The First PC Steel Strand; supplied Three Gorges, Xiaolangdi, Qinshan nuclear plant | Infrastructure contractors | Current status not disclosed in recent filings | — |
| Steel coil processing | Steel coil centres in Guangdong (Dongguan) | Manufacturers in Pearl River Delta | Disposed 30 Jul 2021; residual business closed in FY2023 | — |
Building construction materials segment
| Product line | Description | Target customer | FY2025 revenue (HKD Mn) | Notes |
|---|---|---|---|---|
| Ready-mixed concrete | Produced at Hong Kong concrete batching plants (Siu Ho Wan, Lantau historically cited; additional line Q1 2023) | Contractors on public works and private developments | Included in concrete products 685.9 | Concrete revenue grew from 382.3 (FY2021) to 718.3 (FY2024) |
| Precast concrete products | Precast elements | Contractors | Included in concrete products | — |
| Reinforcing steel distribution | Stockholding and delivery of rebar; Golik Steel described historically as one of Hong Kong's largest rebar suppliers | Contractors | Included in construction steel 1712.7 | Exposed to steel price volatility |
| Off-site cut-and-bend processing | Prefabricated cut and bent rebar delivered to site; described as widely recognised in the industry and generating returns from FY2023 | Contractors seeking labour savings | Processing income 83.9 in FY2024 (last separately disclosed) | Value-added differentiator |
| Decoiling centre | Rebar decoiling (per third-party profile) | Contractors | — | — |
| Transportation services | Delivery services | Contractors | 66.7 in FY2024 (last separately disclosed) | — |
Medical imaging services segment
| Service | Equipment | Target customer | Launch | Notes |
|---|---|---|---|---|
| Assure Medical Imaging (AMI) flagship centre, Tsim Sha Tsui | PET-CT, MRI, CT, ultrasound, mammography, bone density scanning, X-ray | Patients referred by local specialist doctors; insurers; health-check clients | Official launch Nov 2024 | FY2025 revenue HK$41.4 M; segment loss HK$11.6 M; positive EBITDA; PPE impairment HK$15.3 M |
Other
| Service | Detail |
|---|---|
| Golik Capital Limited — money lending | Instalment loans with collateral (HK$3.3 M at 2.46–3.68% p.a.) and one personally guaranteed loan (HK$0.55 M, fully impaired) at end-FY2025 (AR25 Ann.) |
Financial Narrative
All figures HK$ M from audited annual results announcements (AR22 Ann. for FY2021–22; AR23 Ann.; AR24 Ann.; AR25 Ann.). EBIT is defined by the analyst as profit before tax + finance costs − share of results of associate/JV (calc.). EBITDA adds depreciation of PPE and right-of-use assets (post-HKFRS 16; calc.). No amortisation of intangibles is reported.
Income statement
Notes: Diluted EPS equals basic — no potential ordinary shares outstanding in any year. FY2021 includes HK$101.9 M gain on disposal of subsidiaries (pre-tax; HK$5.25 M related tax). FY2021 DPS = interim 2.0 + final 3.0 + special 5.0. FY2025 includes HK$15.3 M PPE impairment and HK$55.8 M onerous-contract provision.
Adjusted view (calc.).
Margins (calc.)
Revenue CAGR FY2021–FY2025 (calc.): −2.8% p.a. (HK$4,053.9 M → HK$3,616.1 M). Excluding the steel coil business disposed in 2021 the underlying trend is flatter, but a like-for-like split is not disclosed.
Commentary. The five-year profile shows three phases. FY2021–22 (COVID & steel-price volatility): revenue peaked at HK$4.27 bn in FY2022, but gross margin troughed at 10.6% as volatile steel prices and Hong Kong's fifth COVID wave hit, and attributable profit fell 62% (also lapping the FY2021 disposal gain). FY2023 (re-opening): margin recovery to 15.1% as Hong Kong construction re-accelerated and cut-and-bend processing scaled; attributable profit +84%. FY2024–25 (deliberate de-scaling): revenue fell 17% in FY2024 as Hong Kong deliveries dropped, but gross margin rose to 18.8–19.2% via mix (wire rope exports, value-added services) and price discipline. Administrative expenses rose 18.5% in FY2025 (to HK$240.2 M), reflecting AMI's first full year. Finance costs fell 59% from FY2023 to FY2025 as bank debt was cut by HK$461 M. The FY2025 effective tax rate rose to 18.7% on Mainland under-provisions (HK$4.4 M) and higher Hong Kong taxable profits.
Interim trend
H1 2023–H1 2025 per interim announcements. H1 2026 figures are derived, not filed values: calculated as SA/S&P trailing-twelve-month figures to 30 Jun 2026 (revenue HK$3,375 M; gross profit HK$666.5 M; net income HK$152.25 M) minus FY2025 plus H1 2025. They imply H1 2026 revenue −13% YoY with attributable profit roughly flat; verify against the H1 2026 interim announcement on HKEXnews.
Balance sheet
Notes: Goodwill/intangibles — none presented on the face of the consolidated statement of financial position in any year (reported as zero above on that basis). FY2023 trade payables include bills payable. Company-reported net gearing (borrowings less cash ÷ total equity): 0.44 (FY21), 0.55 (FY22), 0.18 (FY23), −0.04 (FY24), −0.22 (FY25). FY2025 also carries a new HK$55.8 M provision for onerous contracts (current liability).
Commentary. The balance sheet has been transformed: gross bank debt has fallen 64% from its FY2022 peak (HK$1,250.2 M → HK$444.8 M) while cash rose to HK$805.6 M, swinging the Group from net debt of HK$708.7 M to net cash of HK$360.8 M. The deleveraging was funded by working-capital release (inventories −35% from FY2022; receivables lower in FY2024) and retained earnings, as the dividend payout has stayed at ~25%. Almost all bank debt is short-term (94% current at FY2025), typical of Hong Kong trade-finance and revolving facilities, which creates refinancing dependence but is now more than covered by cash. Equity has compounded at ~6% a year since FY2022 with no share issuance or buybacks.
Cash flow
Source: dividend notes in results announcements; "no purchase, sale or redemption of listed securities" statements in each year.
The consolidated cash-flow statement appears only in the full annual reports (not in the results announcements retrieved). Aggregator figures (SA/S&P show FY2025 "free cash flow" of HK$1,536 M, i.e. 42% of revenue) are implausible against a HK$170.9 M profit and HK$91.9 M net debt reduction, and almost certainly gross up trade-finance loan flows; they are therefore not relied upon. As a proxy, contracted capital commitments were HK$8.3 M at end-FY2025 (FY2024: HK$2.3 M; FY2023: HK$86.1 M, the latter associated with the AMI build-out), indicating a low-capex run-rate. Cash rose by HK$206.1 M in FY2025 while bank debt fell HK$91.9 M and dividends of HK$37.3 M were paid, implying strong internal cash generation of the order of HK$300 M+ before financing (calc., indicative only).
Ratios (calc.)
FY2021 ROE and ROIC are inflated by the HK$101.9 M disposal gain; ex-gain ROIC ≈7.2%. Invested capital = total equity + bank borrowings + lease liabilities − cash.
Commentary. Returns have normalised at a low-double-digit level (ROE ~10–12%, ROIC ~12–13%) — respectable for a commodity-adjacent distributor, and achieved with a now-overcapitalised balance sheet (cash = 28% of total assets). The cash conversion cycle has shortened by ~27 days since FY2021, mainly through longer supplier credit (DPO 11 → 32 days). The rise in receivables over 120 days (HK$66.7 M at FY2025 vs HK$25.5 M at FY2024) is a watch-point for credit quality given contractor distress in Hong Kong.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key products/services |
|---|---|---|
Metal products | Steel wire & wire rope plants in Tianjin, Heshan, Jiangmen | Elevator wire ropes; high-performance lifting ropes; galvanised steel wire; (historically steel coil processing and PC strand) |
Building construction materials | Hong Kong operations | Ready-mixed concrete; precast concrete; rebar distribution; cut-and-bend processing; transportation |
Medical imaging services | Assure Medical Imaging, Tsim Sha Tsui | PET-CT, MRI, CT, ultrasound, mammography, bone densitometry, X-ray |
Other operation (non-reportable) | Golik Capital Limited | Money lending (loan book HK$3.9 M gross at end-FY2025) |
Revenue by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Metal products revenue (HKD Mn) | 1,618.4 | 1,222.3 | 1,172.3 | 1,090.4 | 1,179.4 |
Building construction materials revenue (HKD Mn) | 2,441.6 | 3,051.9 | 2,976.7 | 2,354.4 | 2,398.7 |
Medical imaging services revenue (HKD Mn) | 0 | 0 | 0 | 4.2 | 41.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Metal products segment result (HKD Mn) | 122.2 | 78.9 | 83.7 | 121.1 | 138.8 |
Building construction materials segment result (HKD Mn) | 67.2 | 85.2 | 165.4 | 151.7 | 145.3 |
Results by Segment (FY2024–FY2025)
| Segment | FY2024 | FY2025 |
|---|---|---|
Medical imaging segment result (HKD Mn) | -15.8 | -11.6 |
Segment Margins & Growth (%)
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Metal products margin (%) | 7.6 | 6.5 | 7.1 | 11.1 | 11.8 |
Building construction materials margin (%) | 2.8 | 2.8 | 5.6 | 6.4 | 6.1 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Metal products revenue growth (%) | -24.5 | -4.1 | -7.0 | 8.2 |
Building construction materials revenue growth (%) | 25.0 | -2.5 | -20.9 | 1.9 |
Metal products share of external revenue (%) | 28.5 | 28.2 | 31.5 | 32.5 |
Building construction materials share of external revenue (%) | 71.5 | 71.8 | 68.3 | 66.3 |
Results by Segment (Half-Yearly)
| Segment | H1 2024 | H1 2025 |
|---|---|---|
Metal products revenue (HKD Mn) | 519.2 | 556.5 |
Building construction materials revenue (HKD Mn) | 1,211.5 | 1,248.1 |
Metal products result (HKD Mn) | 44.2 | 68.4 |
Building construction materials result (HKD Mn) | 78.4 | 71.3 |
Other operations result incl. medical (HKD Mn) | -3.6 | -7.8 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 4,053.9 | 4,271.2 | 4,145.7 | 3,445.8 | 3,616.1 |
Cost of sales (HKD Mn) | 3,538.9 | 3,818.3 | 3,520.4 | 2,796.7 | 2,920.8 |
Gross profit (HKD Mn) | 515.0 | 452.9 | 625.2 | 649.1 | 695.3 |
Selling & distribution costs (HKD Mn) | 131.7 | 139.9 | 172.0 | 168.2 | 179.8 |
Administrative expenses (HKD Mn) | 196.1 | 159.9 | 185.0 | 202.8 | 240.2 |
Finance costs (HKD Mn) | 27.1 | 41.5 | 52.9 | 34.3 | 21.7 |
EBIT, calc. (HKD Mn) | 276.4 | 146.9 | 230.7 | 240.8 | 229.9 |
D&A, PPE + ROU (HKD Mn) | 94.4 | 81.2 | 75.0 | 82.8 | 91.5 |
EBITDA, calc. (HKD Mn) | 370.8 | 228.1 | 305.7 | 323.6 | 321.3 |
Profit before tax (HKD Mn) | 249.1 | 106.2 | 178.8 | 208.3 | 210.2 |
Income tax (HKD Mn) | 27.6 | 15.6 | 17.9 | 27.8 | 39.3 |
Profit for the year (HKD Mn) | 221.5 | 90.5 | 160.9 | 180.4 | 170.9 |
Profit attributable to owners (HKD Mn) | 197.6 | 75.7 | 138.9 | 158.1 | 151.2 |
Basic EPS (HK cents) | 34.40 | 13.17 | 24.19 | 27.53 | 26.33 |
Diluted EPS (HK cents) | 34.40 | 13.17 | 24.19 | 27.53 | 26.33 |
Dividend per share incl. special (HK cents) | 10.0 | 5.0 | 6.0 | 6.5 | 6.5 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EBIT excl. disposal gain and PPE impairment (HKD Mn) | 174.5 | 146.9 | 230.7 | 240.8 | 245.1 |
Profit before tax excl. disposal gain and PPE impairment (HKD Mn) | 147.2 | 106.2 | 178.8 | 208.3 | 225.5 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 12.7 | 10.6 | 15.1 | 18.8 | 19.2 |
EBIT margin (%) | 6.8 | 3.4 | 5.6 | 7.0 | 6.4 |
EBITDA margin (%) | 9.1 | 5.3 | 7.4 | 9.4 | 8.9 |
Pre-tax margin (%) | 6.1 | 2.5 | 4.3 | 6.0 | 5.8 |
Net margin, attributable (%) | 4.9 | 1.8 | 3.4 | 4.6 | 4.2 |
Effective tax rate (%) | 11.1 | 14.7 | 10.0 | 13.4 | 18.7 |
Income Statement (Half-Yearly)
| Metric | H1 2023 | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|---|
Revenue (HKD Mn) | 1,961.1 | 1,728.7 | 1,818.1 | 1,577.0 |
Gross profit (HKD Mn) | 282.6 | 321.1 | 355.9 | 327.1 |
Profit attributable to owners (HKD Mn) | 63.1 | 61.6 | 70.6 | 71.6 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 3,147.8 | 3,035.3 | 2,919.3 | 2,711.9 | 2,856.1 |
Property, plant & equipment (HKD Mn) | 491.6 | 490.7 | 465.0 | 524.3 | 471.8 |
Right-of-use assets (HKD Mn) | 280.8 | 226.4 | 161.2 | 160.0 | 153.9 |
Inventories (HKD Mn) | 760.9 | 785.0 | 590.5 | 605.8 | 509.6 |
Trade & bills receivables, net (HKD Mn) | 813.6 | 883.3 | 924.6 | 724.8 | 814.6 |
Cash & cash equivalents (HKD Mn) | 672.7 | 541.6 | 652.1 | 599.5 | 805.6 |
Bank borrowings — current (HKD Mn) | 1,245.8 | 1,250.2 | 906.1 | 498.7 | 416.8 |
Bank borrowings — non-current (HKD Mn) | 0 | 0 | 0 | 38.0 | 28.0 |
Total bank borrowings (HKD Mn) | 1,245.8 | 1,250.2 | 906.1 | 536.7 | 444.8 |
Lease liabilities, total (HKD Mn) | 283.5 | 233.1 | 167.1 | 169.5 | 165.6 |
Net debt, bank borrowings less cash (HKD Mn) | 573.1 | 708.7 | 254.0 | -62.8 | -360.8 |
Net debt incl. leases (HKD Mn) | 856.6 | 941.8 | 421.1 | 106.7 | -195.2 |
Trade payables (HKD Mn) | 103.4 | 130.6 | 261.5 | 275.6 | 253.2 |
Equity attributable to owners (HKD Mn) | 1,193.9 | 1,169.7 | 1,268.5 | 1,382.2 | 1,509.4 |
Non-controlling interests (HKD Mn) | 113.2 | 108.4 | 118.6 | 130.9 | 142.3 |
Total equity (HKD Mn) | 1,307.1 | 1,278.1 | 1,387.1 | 1,513.1 | 1,651.8 |
Goodwill & intangibles (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Working capital, CA less CL (HKD Mn) | 763.2 | 756.6 | 910.3 | 1,022.1 | 1,195.2 |
Book value per share, attributable (HKD) | 2.08 | 2.04 | 2.21 | 2.41 | 2.63 |
Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid to owners of the Company (HKD Mn) | 31.6 | 57.4 | 31.6 | 34.5 | 37.3 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Change in total bank borrowings (HKD Mn) | — | 4.5 | -344.1 | -369.4 | -91.9 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable on average equity (%) | 16.6 | 6.4 | 11.4 | 11.9 | 10.5 |
ROA, profit for year on average total assets (%) | 7.0 | 2.9 | 5.4 | 6.4 | 6.1 |
ROIC, NOPAT on year-end invested capital (%) | 11.4 | 5.6 | 11.5 | 12.9 | 12.8 |
Current ratio (x) | 1.49 | 1.49 | 1.67 | 2.04 | 2.19 |
Bank debt to equity (x) | 0.95 | 0.98 | 0.65 | 0.35 | 0.27 |
Net debt to EBITDA (x) | 1.55 | 3.11 | 0.83 | -0.19 | -1.12 |
Interest coverage, EBIT to finance costs (x) | 10.2 | 3.5 | 4.4 | 7.0 | 10.6 |
Asset turnover (x) | 1.29 | 1.38 | 1.39 | 1.22 | 1.30 |
Days sales outstanding (days) | 73.3 | 75.5 | 81.4 | 76.8 | 82.2 |
Days inventory outstanding (days) | 78.5 | 75.0 | 61.2 | 79.1 | 63.7 |
Days payables outstanding (days) | 10.7 | 12.5 | 27.1 | 36.0 | 31.6 |
Cash conversion cycle (days) | 141.1 | 138.0 | 115.5 | 119.9 | 114.3 |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong revenue (HKD Mn) | 2,310.0 | 2,899.3 | 2,893.8 | 2,350.8 | 2,440.5 |
Mainland China revenue (HKD Mn) | 1,513.9 | 1,069.4 | 1,054.3 | 911.4 | 965.2 |
Rest of world incl. Macau and US (HKD Mn) | 230.0 | 302.4 | 197.6 | 183.5 | 210.4 |
Revenue by Region (FY2024–FY2025)
| Region | FY2024 | FY2025 |
|---|---|---|
United States revenue (HKD Mn) | 110.5 | 134.5 |
Others incl. Macau (HKD Mn) | 73.1 | 75.9 |
Region Margins & Growth (%)
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Hong Kong growth (%) | -0.2 | -18.8 | 3.8 |
Mainland China growth (%) | -1.4 | -13.5 | 5.9 |
Rest of world growth (%) | -34.7 | -7.1 | 14.7 |
Segment Overview — Metal products
| Segment | Hong Kong | Mainland China | United States | Others | Total |
|---|---|---|---|---|---|
Metal products | 11.2 | 955.0 | 134.5 | 75.2 | 1,175.9 |
Building construction materials | 2,387.7 | 10.1 | 0 | 0.7 | 2,398.6 |
Medical imaging | 41.4 | 0 | 0 | 0 | 41.4 |
Locations
| Location | FY2024 | FY2025 |
|---|---|---|
Hong Kong non-current assets (HKD Mn) | 340.5 | 303.5 |
Mainland China non-current assets (HKD Mn) | 345.1 | 331.3 |
Data Point Details
| Data point | Value | Source |
|---|---|---|
Last close | HK$1.17 (9 Oct 2026) | SA |
52-week change | ≈+20% | SA (as of 1 Oct 2026) |
50-day / 200-day moving average | HK$1.16 / HK$1.17 | SA |
Beta (5Y) | 0.40 | SA |
Implied price, Mar 2025 | ≈HK$0.81 (market cap HK$465.2 M ÷ shares) | TipRanks (calc.) |
Implied price, Jun 2025 | ≈HK$0.95 (market cap HK$545.7 M) | TipRanks (calc.) |
Valuation Multiples
| Multiple | Golik | Basis |
|---|---|---|
Market capitalisation | HK$672.0 M | 574.38 M shares |
P/E (FY2025) | 4.4x | EPS HK26.33 cents |
P/E (TTM to Jun 2026) | 4.4x | SA |
P/B | 0.45x | FY2025 attributable equity HK$1,509.4 M (SA quotes 0.39x on a different equity basis) |
EV (incl. NCI and leases, FY2025 balance sheet) | ≈HK$619 M | 672.0 + 142.3 + 444.8 + 165.6 − 805.6 |
EV/EBITDA (FY2025) | ≈1.9x | EBITDA HK$321.3 M (SA: 1.83x on TTM) |
EV/Sales (FY2025) | ≈0.17x | — |
Dividend yield (FY2025 DPS) | 5.6% | HK6.5 cents |
Dividend yield (TTM DPS, derived) | ≈6.0% | HK7.0 cents |
Dividend
| Dividend | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim dividend (HK cents) | 2.0 | 2.0 | 2.5 | 2.5 | 2.5 |
Final dividend (HK cents) | 3.0 | 3.0 | 3.5 | 4.0 | 4.0 |
Special dividend (HK cents) | 5.0 | 0 | 0 | 0 | 0 |
Total dividend (HK cents) | 10.0 | 5.0 | 6.0 | 6.5 | 6.5 |
Payout ratio, total DPS to basic EPS (%) | 29.1 | 38.0 | 24.8 | 23.6 | 24.7 |
Capital Markets
| Item | Status |
|---|---|
Buyback authorisation | General repurchase mandate renewed at each AGM (e.g. 13 Jun 2025); no repurchases executed FY2021–FY2025 |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity (FY2025) | Bank borrowings: HK$416.8 M due within one year; HK$28.0 M due after one year. Lease liabilities: HK$27.4 M current; HK$138.2 M non-current |
Liquidity | Very thin trading; free float ≈36% |
Analyst Conclusions
Management guidance
Qualitative only (AR25 Ann., 27 Mar 2026): 2026 expected to remain challenging and uncertain, with downward pressure from competition and uncertainty over US exports; strategy remains premium products and high-value-added services to keep performance stable. H1 2025 language was "cautiously optimistic" for the full year, which proved broadly accurate (FY2025 profit before impairment rose).
Consensus
No analyst coverage; no consensus estimates exist.
Bull case
-
Deep value with net cash: at ~HK$672 M market cap, the Group trades at ~0.45x book and ~1.9x EV/EBITDA, with net bank cash of HK$360.8 M equal to ~54% of market value; even modest re-rating or higher payouts could drive returns.
-
Earnings mix improving: the wire rope business now generates more segment profit than Hong Kong building materials, at nearly double the margin (11.8% vs 6.1%), supported by OEM relationships and exports.
-
Cyclical optionality in Hong Kong: a growing backlog (HK$1.6 bn, +23%) and the Northern Metropolis pipeline could lift volumes from a depressed base while Golik's balance sheet lets it survive competitor attrition.
Bear case
-
Hong Kong demand trough may be long: management itself sees no improvement and warns of price wars; the HK$55.8 M onerous-contract provision shows backlog quality can deteriorate.
-
Tariff exposure in the growth engine: US revenue (HK$134.5 M, +22%) is the fastest-growing market and explicitly at risk from geopolitics.
-
Capital allocation and governance discount: a controlling family, thin liquidity, ~25% payout and a sub-scale, impaired healthcare venture suggest cash may continue to accumulate rather than be returned, sustaining the discount.
Catalysts & monitorables (next 12 months)
-
H1 2026 interim report: confirm derived revenue decline (~−13%), segment mix, onerous-contract utilisation, and interim DPS (~HK3.0 cents?).
-
US tariff decisions affecting Chinese wire rope exports.
-
Hong Kong public-works funding approvals and Northern Metropolis tender flow.
-
AMI utilisation, insurer partnerships, any further impairment.
-
Aged receivables >120 days and ECL charges.
-
Any special dividend or buyback execution given the HK$805.6 M cash pile.
-
FY2026 annual results (expected late March 2027).
Analyst verdict
Golik Holdings is a financially robust but strategically constrained small-cap whose equity story has quietly changed. Five years ago it was a leveraged Hong Kong building-materials distributor with a Chinese steel-processing appendage, carrying net bank debt of HK$573 M and earning 3–4% net margins in good years. Today it is a net-cash industrial whose most valuable asset is arguably a technically credentialed wire rope franchise — ISO standard author, national manufacturing champion, Caterpillar-recognised supplier — earning double-digit segment margins, bolted to a Hong Kong construction-materials business that is now managed for margin and cash rather than volume.
The financial record supports the "quality improvement" reading: gross margin has nearly doubled since FY2022, ROIC has stabilised near 13%, finance costs have more than halved and equity has compounded without dilution. Yet the top line remains under pressure (FY2021–25 revenue CAGR −2.8%, with H1 2026 apparently down again), both core end-markets are cyclically or structurally weak, the newest growth vector (US exports) is politically exposed, and the healthcare diversification has started by impairing assets.
The valuation — roughly 4.4x earnings, 0.45x book and under 2x EV/EBITDA — already discounts much of this. The binding constraint on shareholder returns is not operations but capital allocation: with cash equivalent to more than half the market capitalisation and a payout ratio near 25%, minority investors depend on the controlling family's willingness to distribute or deploy excess capital productively. Absent that, the discount can persist indefinitely given negligible liquidity and no research coverage.
Key upside triggers would be a higher payout or buyback, a visible Hong Kong order upturn, or evidence that AMI can earn its cost of capital; key downside triggers are US tariff escalation and further onerous-contract or credit losses.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / key dates | Committees | Notes |
|---|---|---|---|---|
Mr. PANG Tak Chung, MH | Executive Director, Chairman | — | Chairman of Nomination Committee; member of Remuneration Committee since 15 Feb 2023 | Co-CODM; MH (Medal of Honour) recipient. |
Mr. HO Wai Yu, Sammy | Executive Director, Vice Chairman; Company Secretary | — | — | FCCA, MHKCS, MHKSI; co-CODM |
Ms. PANG Wan Ping | Executive Director; Chief Executive Officer | CEO since 1 Jan 2022 | Nomination Committee since 30 Jun 2025 | — |
Mr. PANG Chi To | Executive Director | Appointed 1 Aug 2021 | — | — |
Mr. HAI Tuen Tai, Freddie | Independent Non-executive Director | Appointed 16 Jun 2021 | Audit, Remuneration, Nomination | — |
Mr. LUK Kam Fan, Jimmy | Independent Non-executive Director | Appointed c. | Audit, Remuneration, Nomination | — |
Mr. LINN Hon Chung, Ambrose | Independent Non-executive Director | Appointed 1 Feb 2023 | Audit, Remuneration, Nomination | — |
Directors' Remuneration
| Attribute | Status |
|---|---|
Board size | 7 (4 executive, 3 independent non-executive) |
Independence | 43% — meets the HKEX minimum of one-third |
Chair/CEO separation | Separate individuals (Chairman Pang Tak Chung; CEO Pang Wan Ping), but both from the controlling family |
Gender diversity | 1 of 7 directors female (14%) |
Audit Committee | 3 INEDs; established 5 Jan 1999 |
Remuneration Committee | Chairman plus 3 INEDs |
Nomination Committee | Chaired by Chairman; CEO and 3 INEDs |
CG Code compliance | Full compliance stated for FY2024 and FY2025; FY2022 and FY2023 deviations from code provision C.1.6 (two INEDs absent from AGMs) |
Share option scheme | Adopted 14 Jun 2024 (replacing 2014 scheme); no options outstanding (no dilutive potential shares) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
27 Mar 2021 | Mr. Lo Yip Tong (INED) resigned | Board refresh |
16 Jun 2021 | Mr. Hai Tuen Tai appointed INED | Replacement |
1 Jul 2021 | Mr. Lau Ngai Fai (ED) resigned | — |
1 Aug 2021 | Mr. Pang Chi To appointed ED | Next-generation family succession |
1 Jan 2022 | Ms. Pang Wan Ping appointed CEO | Succession |
1 Feb 2023 | Mr. Linn Hon Chung appointed INED | Board refresh ahead of long-tenured INED retirements |
9 Jun 2023 | Mr. Yu Kwok Kan and Mr. Chan Yat Yan (INEDs) retired | Long-tenure INEDs replaced |
30 Jun 2025 | Ms. Pang Wan Ping joined Nomination Committee | Likely to meet HKEX gender-diversity expectations for committees (analyst inference) |
Major Shareholders
| Holder category | Stake | Source |
|---|---|---|
Insiders / substantial shareholders (aggregate) | ≈63.65% | SA/S&P |
Free float | ≈208.8 M shares (≈36.4%) | SA/S&P |
Institutional ownership | Not publicly disclosed / negligible per aggregators | SA/S&P ("n/a") |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type / listing | Relative positioning |
|---|---|---|---|
Wire rope (global) | Bekaert (Bridon-Bekaert Ropes Group) | Euronext Brussels | Global leader in steel wire and ropes; far larger scale |
Wire rope (global) | WireCo WorldGroup | Private (US) | Major global lifting and mining rope supplier |
Wire rope (global) | Teufelberger | Private (Austria) | Premium crane and elevator ropes |
Wire rope (global) | Pfeifer Group | Private (Germany) | Crane ropes and lifting solutions |
Wire rope (global) | Gustav Wolf | Private (Germany) | Elevator rope specialist |
Wire rope (Asia) | Kiswire | Private (Korea) | Large Asian wire and rope maker |
Wire rope (Asia) | Tokyo Rope Mfg. | TSE | Japanese elevator/crane ropes |
Wire rope (Asia) | Usha Martin | NSE/BSE India | Integrated wire rope producer, export-oriented |
Wire rope (China) | Guizhou Wire Rope | SSE (600992) | State-linked domestic rope producer |
Wire rope (China) | Jiangsu Fasten / Langshan wire rope makers | Domestic | Large-volume domestic competitors in steel wire products |
HK concrete | Alliance Construction Materials (CK Infrastructure-affiliated) | Private JV | Major HK aggregates/concrete supplier |
HK concrete | K. Wah Construction Materials | Part of K. Wah International (0173.HK) | Established HK concrete and precast supplier |
HK concrete / cement | China Resources Building Materials | 1313.HK | Cement and concrete in South China and HK |
HK rebar | Shiu Wing Steel | Private | HK's local steel mill and rebar supplier |
HK medical imaging | Private hospitals (e.g. Hong Kong Sanatorium & Hospital, CUHK Medical Centre) and independent imaging centres | Private | Established referral networks and hospital integration |
HK medical imaging | Mainland-linked health-check providers operating in HK | Various | Low-priced packages and digital marketing (cited by Golik as pricing pressure) |
Competitor Detail
| Metric | Golik (FY2025) |
|---|---|
Revenue | HK$3,616.1 M |
Revenue growth | +4.9% |
Gross margin | 19.2% |
EBIT margin | 6.4% (calc.) |
Recent Developments
Litigation, regulatory actions, layoffs or guidance revisions: none identified in the window.



